AIBD 2019
The following article is a part of conference coverage from the 2019 Advances in Inflammatory Bowel Diseases (AIBD) Meeting, being held in Orlando, Florida. The team at MPR will be reporting on the latest news and research conducted by leading experts gastroenterology. Check back for more from the 2019 AIBD Meeting. Combination biologic therapy may…
ACR/ARHP 2018 Annual Meeting
Patients treated with JAK inhibitors for rheumatoid arthritis may be less likely to have low disease activity if they are obese compared with those who are overweight.
AHA 2017 Scientific Sessions
End-stage renal disease patients on dialysis with atrial fibrillation are at high risk for thrombotic complications.
AAAAI 2017
Based on the pathophysiological and clinical characteristics of N-ERD, anti-IL 5 therapy may be effective in this patient subgroup.
ACR/ARHP 2016 Annual Meeting
The trial compares short- and long-term outcomes of Cimzia and Humira in RA
ACR/ARHP 2016 Annual Meeting
Uveitis should be suspected in patients with ankylosing spondylitis (AS) who have high lesion counts, antistreptolysin O (ASO) and circulating immune complex (CIC) titers
ACR/ARHP Annual Meeting 2013
Tofacitinib 5mg or 10mg twice daily showed a consistent safety profile and sustained efficacy over 5 years in long-term extension studies for patients with rheumatoid arthritis, as presented at the 2013 ACR/ARHP Annual Meeting.
ACR/ARHP Annual Meeting 2013
At the 2013 ACR/ARHP Annual Meeting, study authors presented that patients with active rheumatoid arthritis (RA) despite methotrexate (MTX), certolizumab pegol (CZP) + MTX maintained reduction in signs and symptoms through 5 years.
